<DOC>
	<DOCNO>NCT01608711</DOCNO>
	<brief_summary>The purpose study continue safety immunogenicity AGS-1C4D4 administer combination gemcitabine subject previously treat protocol 2008002 .</brief_summary>
	<brief_title>A Study AGS-1C4D4 Pancreatic Cancer Subjects Previously Treated Protocol 2008002</brief_title>
	<detailed_description>Subjects receive maintenance dose AGS-1C4D4 every 3 week ( Q3W ) addition gemcitabine administration . If subject grade 4 adverse event consider related AGS-1C4D4 anytime study , AGS-1C4D4 treatment discontinue subject . Subjects continue tumor status assess computerize tomography ( CT ) magnetic resonance ( MRI ) scan accord Response Evaluation Criteria Solid Tumors ( RECIST Version 1.1 ) guideline every eight week ( Q8W ) . Subjects without evidence disease progression continue receive AGS-1C4D4 gemcitabine intolerability , disease progression consent withdrawal . Subjects discontinue AGS-1C4D4 reason undergo end study visit 4 week last AGS-1C4D4 infusion .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject stable disease well per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion v.1.1 . Protocol 2008002 More 6 week ( 2 dos ) lapse time last infusion AGS1C4D4 Protocol 2008002 Use follow prohibited medication / therapy : Monoclonal antibody therapy , AGS1C4D4 Chemotherapy , gemcitabine Investigational therapy AGS1C4D4 Erlotinib ( Tarceva ) Any clinical condition would allow safe conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>AGS-1C4D4</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>ASP6182</keyword>
</DOC>